From autonomous robotaxis, to blind box and nostalgia marketing here are 5 of the most innovative business moves and trends ...

Novo Nordisk just got a big win from the FDA, and it could change the weight-loss medicine industry again.

Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts.

Novo Nordisk’s oral Wegovy wins FDA approval, outperforming rivals in weight loss. Discover why NVO stock is undervalued now.

The first pills are expected to hit the market next month and attract people who don’t want to give themselves shots.

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The U.S. Food and Drug Administration’s ...

Major stock indexes ended higher for a fourth straight session Tuesday, with the S&P 500 setting a fresh closing record, ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion ...

A major health care divide is coming in 2026. Some Americans may finally catch a break on rising costs, as the first ...

Wall Street closed higher and reached more records Wednesday on a holiday-shortened trading day. The S&P 500 index rose 22.26 ...

Asian shares are mixed in thin holiday trading, with most markets in the region and elsewhere closed for Christmas ...